Gu Oncology Now

Efficacy and Toxicity of 177Lu-PSMA-617 for mCRPC in a Real-World Setting 5:45
Efficacy and Toxicity of 177Lu-PSMA-617 for mCRPC in a Real-World Setting GU Oncology Now 61 2 дня назад
Sequential Endoluminal Chemotherapy for Non-Invasive High-Grade UTUC 8:33
Sequential Endoluminal Chemotherapy for Non-Invasive High-Grade UTUC GU Oncology Now 25 4 дня назад
Updated ENVISION Data: UGN-102 Shows 82.3% Duration of Response in LG-IR-NMIBC 7:32
Updated ENVISION Data: UGN-102 Shows 82.3% Duration of Response in LG-IR-NMIBC GU Oncology Now 27 5 дней назад
Safety Considerations for 89Zr-girentuximab PET/CT Imaging in ccRCC 4:36
Safety Considerations for 89Zr-girentuximab PET/CT Imaging in ccRCC GU Oncology Now 0 5 дней назад
SNMMI 2024: Dosimetry of 177Lu-PSMA RLTs, FLEX-MRT, and More 6:23
SNMMI 2024: Dosimetry of 177Lu-PSMA RLTs, FLEX-MRT, and More GU Oncology Now 36 10 дней назад
Nuclear Medicine Highlights From the SNMMI 2024 Annual Meeting 3:15
Nuclear Medicine Highlights From the SNMMI 2024 Annual Meeting GU Oncology Now 28 10 дней назад
PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC 10:20
PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC GU Oncology Now 105 12 дней назад
NECTIN4 Amplification Predicts Response to EV in Metastatic Urothelial Carcinoma 9:03
NECTIN4 Amplification Predicts Response to EV in Metastatic Urothelial Carcinoma GU Oncology Now 27 12 дней назад
Refractory RCC: Third-Line Treatment Considerations 5:36
Refractory RCC: Third-Line Treatment Considerations GU Oncology Now 39 13 дней назад
Improving Outcomes in Patients With Chromophobe, Papillary RCC 14:37
Improving Outcomes in Patients With Chromophobe, Papillary RCC GU Oncology Now 66 13 дней назад
CheckMate 274: Estimating the Underlying Cure Fraction for Patients With High-Risk MIUC 3:43
CheckMate 274: Estimating the Underlying Cure Fraction for Patients With High-Risk MIUC GU Oncology Now 100 5 месяцев назад
Nuclear Medicine Highlights From the SNMMI 2024 Annual Meeting 3:15
Nuclear Medicine Highlights From the SNMMI 2024 Annual Meeting GU Oncology Now 28 10 дней назад
Next-Generation Immunotherapy for NMIBC: QUILT 2.005 and QUILT 3.032 7:14
Next-Generation Immunotherapy for NMIBC: QUILT 2.005 and QUILT 3.032 GU Oncology Now 2,777 1 месяц назад
Trastuzumab Deruxtecan FDA Approval and Future Directions for HER2-Positive Bladder Cancer 14:21
Trastuzumab Deruxtecan FDA Approval and Future Directions for HER2-Positive Bladder Cancer GU Oncology Now 70 1 месяц назад
Next-Generation Therapies in RCC: Examining Tivozanib and Belzutifan 8:40
Next-Generation Therapies in RCC: Examining Tivozanib and Belzutifan GU Oncology Now 120 3 месяца назад
Genomic Signatures Associated With Adverse Pathologic Features at Radical Prostatectomy 4:22
Genomic Signatures Associated With Adverse Pathologic Features at Radical Prostatectomy GU Oncology Now 47 1 месяц назад
Previewing the 2024 ASCO Genitourinary Cancers Symposium 7:37
Previewing the 2024 ASCO Genitourinary Cancers Symposium GU Oncology Now 355 5 месяцев назад
Expert Panel Shares Forward-Looking Thoughts on RCC Treatment, Clinical Trials 3:48
Expert Panel Shares Forward-Looking Thoughts on RCC Treatment, Clinical Trials GU Oncology Now 85 4 месяца назад
AI Modeling, KEYNOTE-992, MAIN-CAV, and Platinum-Eligibility Criteria in Bladder Cancer 9:15
AI Modeling, KEYNOTE-992, MAIN-CAV, and Platinum-Eligibility Criteria in Bladder Cancer GU Oncology Now 62 5 месяцев назад
68Ga-RM2 PET-MRI Versus MRI Alone for Biochemically Recurrent Prostate Cancer 7:24
68Ga-RM2 PET-MRI Versus MRI Alone for Biochemically Recurrent Prostate Cancer GU Oncology Now 124 2 месяца назад
Defining the Biology of Upper Tract Urothelial Carcinoma and Therapy Implications 10:47
Defining the Biology of Upper Tract Urothelial Carcinoma and Therapy Implications GU Oncology Now 399 6 месяцев назад
Dr. Guru Sonpavde on Nivolumab, Gem-Cis FDA Approval and Role in Treating Metastatic Bladder Cancer 4:18
Dr. Guru Sonpavde on Nivolumab, Gem-Cis FDA Approval and Role in Treating Metastatic Bladder Cancer GU Oncology Now 77 3 месяца назад
ASCO® GU Data Updates in Frontline Kidney Cancer: Was Anything Practice Changing? 5:47
ASCO® GU Data Updates in Frontline Kidney Cancer: Was Anything Practice Changing? GU Oncology Now 84 4 месяца назад
Advanced, Metastatic Kidney Cancer: Favorable and Very Favorable Risk Stratification 1:35
Advanced, Metastatic Kidney Cancer: Favorable and Very Favorable Risk Stratification GU Oncology Now 45 2 недели назад
Carboplatin Versus Cisplatin in UTUC 10:40
Carboplatin Versus Cisplatin in UTUC GU Oncology Now 83 3 месяца назад
Bladder Cancer Roundup: Enfortumab Vedotin, Nivolumab, and More 5:29
Bladder Cancer Roundup: Enfortumab Vedotin, Nivolumab, and More GU Oncology Now 36 2 недели назад
How is Precision Medicine Utilized in Advanced Prostate Cancer? 8:43
How is Precision Medicine Utilized in Advanced Prostate Cancer? GU Oncology Now 106 1 год назад
Uromigos Live 2023: Frontline Metastatic Renal Cancer: Time for Reflection 47:47
Uromigos Live 2023: Frontline Metastatic Renal Cancer: Time for Reflection GU Oncology Now 509 7 месяцев назад

Сейчас ищут